Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease

BACKGROUND: The optimal chemotherapy regimen for non-small-cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) remains unknown. Therefore, in this study, we investigated the real-world efficacy and safety of carboplatin (CBDCA) plus nab-paclitaxel (nab-PTX) as a first-line regimen...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Manag Res
Main Authors: Igawa, Satoshi, Nishinarita, Noriko, Takakura, Akira, Ozawa, Takahiro, Harada, Shinya, Kusuhara, Seiichiro, Niwa, Hideyuki, Hosotani, Shinji, Sone, Hideyuki, Nakahara, Yoshiro, Fukui, Tomoya, Mitsufuji, Hisashi, Yokoba, Masanori, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Naoki, Katsuhiko
格式: Artigo
語言:Inglês
出版: Dove Medical Press 2018
主題:
Original Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6298387/
https://ncbi.nlm.nih.gov/pubmed/30588105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S189556
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍